Pacritinib | PRE-VENT
Stage (next event)
Phase 3 (Top-line Data)
Catalyst Info & Data Links
TITLE: Pacritinib for COVID-19 - Top-line Data
ClinicalTrial.gov (NCT04404361): PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer
WHAT IS THE NEXT CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
MECHANISM OF ACTION / RATIONALE
An orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Pacritinib competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, and so caspase-dependent apoptosis. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity (learn more - National Cancer Institute)
Updated by HC
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post